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Abstract
To evaluate the role of multiparametric magnetic resonance imaging (mpMRI) in predicting upgrading, upstaging, and extraprostatic
extension in patients with low-risk prostate cancer (PCa). MpMRI may reduce positive surgical margins (PSM) and improve nerve-
sparing during robotic-assisted radical prostatectomy (RARP) for localized prostate cancer PCa.
This was a retrospective, monocentric, observational study. We retrieved the records of patients undergoing RARP from January
2012 to December 2013 at our Institution. Inclusion criteria were: PSA <10ng/mL; clinical stage <T3a; biopsy Gleason score <7;
prostate mpMRI performed preoperatively at our Institution; intraoperative FSA of the posterolateral aspects of the specimen.
All the identiﬁed lesions were scored according to the Prostate Imaging Reporting and Data System (PIRADS). We considered the
lesion with the highest PIRADS score as index lesion. All the included patients underwent nerve-sparing RARP. During surgery, the
specimen was sent for FSA of the posterolateral aspects. The surgeon, according to the localization scheme provided by thempMRI,
inked the region of the posterolateral aspect of the prostate that had to be submitted to FSA.
We evaluated association between clinical features and PSM, upgrading, upstaging, and presence of unfavorable disease.
Two hundred ﬁfty-four patients who underwent nerve-sparing RARP were included. PSM rate was 29.13% and 15.75% at FSA
and ﬁnal pathology respectively. Interestingly, the use of FSA reduced PSM rate in pT3 disease (25.81%). Higher PIRADS scores
demonstrated to be related to high probability of upgrading and upstaging. This signiﬁcativity remains even when considering
PIRADS 2–3 versus 4 versus 5 and PIRADS 2–3 versus 4–5. Also PSM at FSA were associated with higher probability of upgrading
and upstaging.
PIRADS score and FSA resulted to be strictly related to grading and staging, thus being able to predict upgrading and/or upstaging
at ﬁnal pathology.
Abbreviations: AUC = area under curve, BCR = biochemical recurrence, BPH = benign prostatic hyperplasia, CI = conﬁdence
interval, CSM = cancer-speciﬁc mortality, DCE = dynamic contrast-enhanced, DWI = diffusion-weighted, EPE = extraprostatic
extension, ESUR = European Society of Urogenital Radiology, FSA = frozen-section analysis, GS = Gleason score, mpMRI =
multiparametric magnetic resonance imaging, NVB = neurovascular bundle, OR = odds ratio, PCa = prostate cancer, PIRADS =
Prostate Imaging Reporting and Data System, PSA = prostatic-speciﬁc antigen, PSM = positive surgical margins, RARP = robotic-
assisted radical prostatectomy, ROC = receiver operating characteristics, ROI = region of interest, T2w = T2-weighted.
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11. Introduction
Multiparametric magnetic resonance imaging (mpMRI)
and frozen-section analysis (FSA) may play an important role
in reducing positive surgical margins (PSM) during nerve-
sparing robotic-assisted radical prostatectomy (RARP) for
localized prostate cancer (PCa). Anyway, only a few evidences
supporting the combined use of these 2 instruments are
available.[1]
Recently, mpMRI has been applied not only to identiﬁcation of
lymph nodes involvement but also to the identiﬁcation of high-
risk cancer areas within the prostate, which are sometimes missed
by standard prostate biopsy.[2]
Moreover, mpMRI proved to be reliable in identifying
extraprostatic extension (EPE) or seminal vesicles involvement,[3]
and in detecting anterior zone PCa, which is often missed by
prostate biopsy.[4]
Bianchi et al. Medicine (2016) 95:40 MedicineThus, mpMRI is becoming a very useful planning tool in the
clinical pathway for localized PCa, gaining a role in the risk
stratiﬁcation.
MpMRI includes high-resolution T2-weighted sequences
(T2w), diffusion-weighted sequences (DWI), dynamic contrast-
enhanced images (DCE), and spectroscopy.
T2w sequences have high spatial resolution (0.6  0.7mm
pixels), and can deﬁne the relationships between the suspect
lesion and the prostatic capsule, reaching a sensitivity of 48% to
88% and a speciﬁcity of 44% to 81%.[5,6]
DWI sequences, which measure the diffusion of water
molecules within the tissues (reduced in cancerous tissue),
associated with high-resolution T2w sequences, enhance sensi-
tivity and speciﬁcity to 85% to 90%.[7]
DCE sequences provide with a perfusional map of the region of
interest (ROI) identiﬁed by the previous sequences. In high-grade
malignant lesions, early enhancement and early washout are
present, while in benign prostatic hyperplasia (BPH) areas
washout is slow.[8] Adding these sequences brings sensitivity and
speciﬁcity to 90% to 95%.[9]
Spectroscopy is a technique that indirectly measures the
concentration of some metabolites within the ROI. Particularly,
intracellular concentrations of choline, creatine (which increase
in cancerous lesions), and citrate (which decrease with growing
cancer grade and volume) are estimated. Spectroscopy brings
speciﬁcity to 98%, but, on the other hand, sensitivity is only
53%.
Correct interpretation of mpMRI may be challenging, so the
European Society of Urogenital Radiology (ESUR) produced a
standardized score to describe prostatic lesions. This system,
similarly to the existing Breast Imaging Reporting and Data
System, has been called Prostate Imaging Reporting and Data
System (PIRADS).[10]
The aim of the PIRADS is to uniform interpretation of mpMRI
images to predict the clinical relevance of the identiﬁed lesions.
This probability is expressed by means of a score ranging from
1 (very unlikely) to 5 (very likely).
The validity of the PIRADS has been conﬁrmed by Kuru
et al,[11] who compared PIRADS score assigned to prostatic
lesions with biopsy Gleason score (GS).
FSA can be implied to identify EPE and so to decide whether or
not to spare the neurovascular bundle (NVB):[12] this way, PSM
rates can be reduced.
FSA of macroscopically suspicious prostatic tissue fragments
resulted to have low sensitivity.[13] Sensitivity improves when all
the posterolateral aspects of the prostate, which are in contact
with the NVB, are examined.[12]
Even if PSM alone are not associated with an increase of
cancer-speciﬁc mortality (CSM) in the 15 years following radical
prostatectomy, reducing PSM results in less biochemical
recurrences (BCR), secondary therapies, and patient anxiety.[14]
The aim of this study was to evaluate the role of prostate
mpMRI as a predictor of upgrading, upstaging, and EPE and the
use of FSA as a predictor of PSM.2. Materials and methods
This was a retrospective, monocentric, observational study. We
retrieved the records of patients undergoing nerve-sparing RARP
from January 2012 to December 2013 at our Institution.
Inclusion criteria were: initial prostatic-speciﬁc antigen (PSA)
<10ng/mL; clinical stage <T3a; biopsy GS<7; prostate mpMRI
performed preoperatively at our Institution; intraoperative FSA2of the posterolateral aspects of the specimen. The Institutional
Review Board approved the study.
Patients with history of previous prostatic surgery (e.g., for
BPH), preoperative hormone therapy, previous external beam
radiotherapy, or brachytherapy were excluded. All the identiﬁed
lesions were scored according to PIRADS. We considered the
lesion with the highest PIRADS score as index lesion. Two
experienced radiologists (GP and SA) evaluated all the mpMRIs,
reporting their conclusions on a standard reporting scheme, a
useful tool for the surgeon to localize the lesions (Fig. 1).
All mpMRIs were performed with a 1.5 Tesla device. T2w,
DWI, and DCE sequences were obtained.
All the included patients underwent nerve-sparing RARP.
During surgery, after the removal of the prostate, the specimen
was sent for FSA of the posterolateral aspects. The surgeon,
according to the localization scheme provided by the mpMRI,
inked the region of the posterolateral aspect of the prostate that
had to be submitted to FSA.
Experienced uropathologists prepared the specimen for FSA;
5mm sections were analyzed at optical microscopy. FSA results
were reported to the surgeon: margins were deﬁned as negative,
focally positive (1mm), positive (>1mm), or with cancer
present at <1mm from the inked margin.
In case of extensively positive margin, total NVB removal
was performed; in case of focally positive margin, only partial
resection of the NVB was performed.2.1. Statistical analysis
PSM were deﬁned as the presence of cancer on the surgical
margin during FSA or at ﬁnal pathology. The disease was deﬁned
“unfavorable” when ﬁnal pathology reported at least an
upgrading (GS≥7) or an upstaging≥pT3a. Association between
clinical features and PSM, upgrading, upstaging, and presence of
unfavorable disease has been evaluated with the x2 test or Fisher
test for categorical variables. Non-parametric Wilcoxon test has
been applied to independent samples, while the T test has been
used for continuous variables.
By means of non-conditioned logistic regression models, we
calculated the odds ratios (ORs) with their conﬁdence intervals
(CIs) for PSM, upgrading, upstaging, and unfavorable disease.
With each model, we evaluated PIRADS 2–3 versus PIRADS 4
versus PIRADS 5 lesions, and PIRADS 2–3 versus PIRADS 4–5
lesions.
Finally, we compared each model including or not including
PIRADS score, and designed the receiver operating characteristics
(ROC) curves to ﬁnd out if the difference between the areas under
curve (AUC) was signiﬁcant according to the De Long test.[15]
For all analyses, a P value<0.05 was used to indicate
statistically signiﬁcance.
Statistically analysis was performed with SAS software ver.
9.2.3. Results
Two hundred ﬁfty-four patients who underwent nerve-sparing
RARP were included. Mean age was 62.6±7.17 years. Mean
pretreatment PSA was 6.1±1.95ng/mL.
Two hundred two (79.53%) patients had T1 disease (1 T1a
and 202 T1c). Fifty-two (20.47%) patients had cT2 disease (49
with cT2a and 3 with cT2b disease).
Preoperative mpMRI showed at least 1 PIRADS 5 lesion in 96
patients (37.8%), at least 1 PIRADS 4 in 102 (40.16%), 1
Figure 1. Standard reporting scheme for lesions identiﬁed by mpMRI. mpMRI = multiparametric magnetic resonance imaging.
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(4.33%).
During surgery, 191 (75.20%) patients had bilateral nerve-
sparing, 47 (18.50%) monolateral nerve-sparing, while, in 16
(6.30%) patients, nerve-sparing was not feasible.
Median time to receive FSA results was 35 minutes.
At ﬁnal pathology, staging was pT2a in 23 (9.05%) patients,
pT2b in 5 (1.97%), pT2c in 164 (64.57%), pT3a in 56 (22.05%),
and pT3b in 6 (2.46%). One patient (0.39%) had GS 5, 124
patients (48.82%) had GS 6, 125 (49.21%) GS 7, 3 (1.18%) GS
8, and 1 (0.39%) GS 9.
The features of the included population are shown in Table 1.
First, we analyzed PSM rates. 74 patients (29.13%) had PSM
at FSA, while 40 (15.75%) had PSM at ﬁnal pathology (P<0.05).
Of these 74 patients, 44 (59.46%) had T2 disease, while 30
(40.54%) had T3 (Table 2).
We then analyzed PSM rates according to pathological stage.
Of 192 patients with pT2 disease, 44 (22.92%) had PSM at FSA
and 24 (12.50%) had PSM at ﬁnal pathology. Of the 44 patients
with PSM at FSA, 38 had negative margins at ﬁnal pathology3after radicalization. Of 148 with pT2 disease and negative
margins at FSA, 18 had PSM at ﬁnal pathology (Table 3).
Of 62 patients with pT3 disease, 30 (48.39%) had PSM at FSA;
of them, 21 had negative margins at ﬁnal pathology after
radicalization. Of the 31 pT3 patients with negative margins at
FSA, 7 had PSM at ﬁnal pathology (Table 4).
Of 198 patients with PIRADS 4 or 5 lesions, 64 (32.32%) had
PSM at FSA; of them, 28 resulted to be pT3 and 36 pT2. Thirty-
two patients (16.16%) had PSM at ﬁnal pathology (15 pT3 and
17 pT2) (Table 5).
One hundred eighty patients had negative margins at FSA; of
them, 25 (13.89%) had PSM at ﬁnal pathology.
We investigated the association between the preoperative
clinical features of patients who had PSM at FSA or at ﬁnal
pathology and PIRADS score at mpMRI.
Interestingly, age resulted to be statistically signiﬁcant. Patients
aged 63.5±7.8 are more likely to have PSM than patients aged
61.9±6.7 (P=0.02).
Higher PIRADS scores resulted to be related to the probability
of PSM (Table 6). Statistical signiﬁcance was present at univariate
Table 1
Features of the included population.
N (%)
Age
∗
62.6 (±7.17)
Clinical stage
cT1a-1c 202 (79.53%)
cT2a-2c 52 (20.47%)
PSA
∗
6.1 (±1.95)
Pathological stage
pT2a 23 (9.05%)
pT2b 5 (1.97%)
pT2c 164 (64.57%)
pT3a 56 (22.05%)
pT3b 6 (2.46%)
Gleason Score sum
5 1 (0.39%)
6 124 (48.82%)
7 125 (49.21%)
8 3 (1.18%)
9 1 (0.39%)
PIRADS
2 11 (4.33%)
3 45 (17.72%)
4 102 (40.16%)
5 96 (37.80%)
PIRADS = Prostate Imaging Reporting and Data System, PSA = prostatic-speciﬁc antigen.
∗
= (±SD).
Table 3
Surgical margins in patients with pT2 disease.
Final pathology
pT2 FSA Positive Negative
Positive 44 (22.92%) 6 38
192 Negative 148 18 130
Total 192 24 (12.5%) 168
FSA = frozen-section analysis.
Bianchi et al. Medicine (2016) 95:40 Medicine(P=0.01), but not at multivariate analysis, as shown by the ROC
curves (Fig. 2A and B).
Considering the association between the preoperative features
of patients with pT3 disease, PIRADS score, and FSA, all
univariate analyses demonstrated statistical signiﬁcance.
Patients with cT2 disease resulted to have a 3-fold probability
(OR 3.2) to have pT3 disease when compared with patients with
T1c disease (P=0.002 at multivariate analysis).
From this analysis, we showed that patients with PIRADS 5
lesions at mpMRI had higher probability to present with pT3
disease (OR 3.41; P=0.001 at multivariate analysis). Similarly,
patients with PSM at FSA had higher probability to have pT3
disease (OR 2.59; P=0.004).
When grouping mpMRI-evidenced lesions in PIRADS 2–3
and 4–5, statistical signiﬁcance is lost, since patients with
PIRADS 4 lesion had higher probability to have T3 disease (OR
1.17), but not in statistically signiﬁcant way (P=0.21) (Table 7
and Fig. 3).
We also analyzed the association between features of patients
with GS≥7 and PIRADS score. PIRADS score was related to the
probability of a GS upgrade to≥7 at ﬁnal pathology both at
univariate (P=0.0003) and multivariate analyses (P=0.02). InTable 2
PSM at FSA and ﬁnal pathology according to pathological staging.
pT2 (% PSM) pT3 (% PSM) Total (% PSM)
Margins at FSA
Negative 148 32 180 (70.87)
Positive 44 (22.92) 30 (48.39) 74 (29.13)
Margins at ﬁnal pathology
Negative 168 46 214 (84.25)
Positive 24 (12.5) 16 (25.81) 40 (15.75)
FSA = frozen-section analysis, PSM = positive surgical margins.
4fact, patients with at least 1 PIRADS 4 lesion had almost twice the
probability to have GS≥7, while patients with PIRADS 5 had
more than 3 times the probability to have GS≥7 when compared
with patients with PIRADS 2 to 3 lesions.
Similarly signiﬁcant is the association between GS at ﬁnal
pathology and FSA. In fact, patients with PSM at FSA had almost
3 times the probability to have a GS upgrade to≥7 (OR 2.7; P=
0.001). Signiﬁcance is also present when grouping patients with
PIRADS 4–5 versus PIRADS 2–3 (Table 8, Fig. 4).
Finally, we evaluated upgrading and upstaging at ﬁnal
pathology in correlation with the preoperative features of the
included patients.
Higher PIRADS scores demonstrated to be related to high
probability of upgrading and upstaging (OR 4.72 for PIRADS 5);
both at univariate and multivariate analyses, P value was<0.05.
This signiﬁcativity remains even when considering PIRADS 2–3
versus 4 versus 5 and PIRADS 2–3 versus 4–5.
Also PSM at FSA were associated with higher probability of
upgrading and upstaging (P<0.05 at univariate analysis) (Table 9
and Fig. 5).
4. Discussion
In our study, PSM rate was 29.13% and 15.75% at FSA and ﬁnal
pathology respectively. Interestingly, the use of FSA reduced PSM
rate in pT3 disease, which resulted 25.81%, lower than what is
reported in the literature.[16]
We did not distinguish between focally and extensively positive
surgical margins. Our incidence of PSM at FSA can also be
explained by our attempt to perform intrafascial nerve-sparing,
which is more prone to PSMbut demonstrated signiﬁcantly better
sexual function outcomes.[17]
In the present series, RARP were performed by 8 different
surgeons, of which 3 were “high-volume” surgeons (> 50 cases
per year), while 5 performed less than 50 cases per year. The use
of FSA, guided by mpMRI, allowed reducing PSM despite this
fact.
PSM, deﬁned as the presence tumor at the inked margin of the
prostatectomy specimen, are a risk factor for disease progression
after surgery.[18] The impact of PSM on cancer-related outcome
has been studied extensively, even if a clear association betweenTable 4
Surgical margins in patients with pT3 disease.
Final pathology
pT3 FSA Positive Negative
62 Positive 30 (48.39%) 9 21
Negative 32 7 25
Total 62 16 (25.81%) 46
FSA = frozen-section analysis.
Table 5
Margins and pathological stage in patients with PIRADS 4 or 5
lesions.
Margins at FSA Margins at ﬁnal pathology
PIRADS 4 or 5 Positive Negative Positive Negative
pT3 55 28 27 15 40
pT2 143 36 107 17 126
Total 198 64 134 32 166
FSA = frozen-section analysis, PIRADS = Prostate Imaging Reporting and Data System.
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study, indicating that patients with PSM had a 1.7-fold higher
risk of death compared with those without.[19]
The mean PSM rate reported in large systematic review was
9% in pT2 diseases, 37% in pT3, and 50% in pT4,[16] which is
consistent with the data we obtained from our study.
Sooriakumaran et al[20] showed how surgical experience
heavily inﬂuences the incidence of PSM.
The use of FSA to reduce PSM has been previously reported. In
2002, Goharderakhshan et al[21] reported the experience of 101
patients undergoing open mono- or bilateral nerve-sparing
radical prostatectomy: FSA has been performed on the
prostatectomy specimens, which was consistent with ﬁnal
pathology in 91% of cases. Positive and negative predictive
value of FSA resulted to be 73% and 94% respectively.
More recently, Schlomm et al reported the outcomes on 5392
patients who underwent FSA of the whole margin near to the
NVB during nerve-sparing radical prostatectomy. PSM occurred
in 25% of cases. After radicalization of the involved NVB, 86%
had negative margins at ﬁnal pathology.[22] Similar results have
been reported by Von Bodman et al.[23]Table 6
Association between the clinical features of the patients and PSM
∗
: un
versus PIRADS 5, and PIRADS 2–3 versus PIRADS 4–5.
PSM
∗
Yes N (%) No N (%) P
Age† 63.5 (±7.8) 61.9 (±6.7)
Clinical stage
cT1a-1c 73 (74%) 129 (83%)
cT2a-2c 26 (26%) 26 (17%)
PSA† 6.2 (±1.9) 5.9 (±2.0)
PIRADS
2 0 (0%) 11 (7%)
3 16 (16%) 29 (19%)
4 38 (38%) 64 (41%)
5 45 (46%) 51 (33%)
Age† 63.5 (±7.8) 61.9 (±6.7)
Clinical stage
cT1a-1c 73 (74%) 129 (83%)
cT2a-2c 26 (26%) 26 (17%)
PSA† 6.2 (±1.9) 5.9 (±2.0)
PIRADS
2–3 16 (16%) 40 (26%)
4–5 83 (84%) 115 (74%)
Signiﬁcative ORs and P values are in bold.
FSA = frozen-section analysis, PIRADS = Prostate Imaging Reporting and Data System, PSA = prosta
∗
PSM at FSA or ﬁnal pathology.
† ±SD.
‡ T test for continuous variables; x2 test or Fisher exact test for categorical variables.
5In the present study, signiﬁcant association emerged between
PIRADS 4–5 and PSM at FSA, upgrading and upstaging.
Higher PIRADS scores resulted to be related to higher
probability of pT3 disease; particularly, this probability was
statistically signiﬁcant for PIRADS 5. In fact, mpMRI with T2-
weighted sequences, DCE, and spectroscopy reaches almost 80%
accuracy in diagnosing EPE.[24]
In our series, rather than with biopsy GS as reported by Kuru
et al[11] PIRADS seem to have a good correlation with GS on the
surgical specimen.
MpMRI excludes the presence of a clinically relevant
prostate cancer with a speciﬁcity and negative predictive value
of 90% to 95%. Thus, potential applications of mpMRI to
prostate cancer diagnosis can be: improve prostate biopsy
sensitivity in patients with intermediate- and high-risk prostate
cancer; reduce low-risk disease overdiagnosis; avoid biopsy in
younger patients with nonsuspicious mpMRI; exclude high-risk
disease in patients with elevated PSA and negative prostate
biopsies.[25]
MpMRI is particularly useful to identify high-grade and
signiﬁcant-volume cancers. T2-weighted sequences precisely
identify disease foci when GS is≥7 and volume is ≥ 0.5
cm3.[26] DW sequences and spectroscopy are related to GS too.
Villeirs et al[27] conﬁrmed how mpMRI can identify a GS ≥7
lesion with a 93% sensitivity and a 93% speciﬁcity, which is
really impressive when compared with a 68% sensitivity for GS 6
disease.
Marcus et al studied the inﬂuence of mpMRI on risk
stratiﬁcation of prostate cancer. On 71 total patients, 12
(16.9%) have reclassiﬁed to a higher risk class due to mpMRI
ﬁndings, while in 6 patients (8.5%) mpMRI changed the
therapeutic strategy. MpMRI speciﬁcity for pT3 disease resulted
to be 92.9%.[28]ivariate andmultivariate analysis with PIRADS 2–3 versus PIRADS 4
value‡ Multivariate odds ratio (95% CI) P value
0.02 1.02 (0.98–1.06) 0.27
0.19 0.17
1.00 (reference)
1.56 (0.83–2.95)
0.25 1.07 (0.94–1.22) 0.33
0.01
1.00 (reference)
1.42 (0.69–2.89) 0.93
1.92 (0.93–3.94) 0.09
0.02 1.02 (0.99–1.06) 0.22
0.19 0.15
1.00 (reference)
1.60 (0.85–3.01)
0.25 1.08 (0.94–1.23) 0.29
0.07 0.14
1.00 (reference)
1.64 (0.85–3.15)
tic-speciﬁc antigen, PSM = positive surgical margins.
Figure 2. Comparison between ROC curves for PSM at FSA or ﬁnal pathology. A, All PIRADS score (P=0.39). B, PIRADS 2–3 versus PIRADS 4–5 (P=0.39).
FSA = frozen-section analysis, PIRADS = Prostate Imaging Reporting and Data System, PSM = positive surgical margins, ROC = receiver operating
characteristics.
Bianchi et al. Medicine (2016) 95:40 MedicineMpMRI has also been suggested to improve functional
outcomes in patients undergoing nerve-sparing RARP. McClure
et al demonstrated that mpMRI could change surgical strategy in
nerve-sparing RARP. In 28 of 104 included patients, mpMRI
provided the surgeon with data that changed the decision of
performing a nerve-sparing procedure: interestingly, 17 patients,Table 7
Association between clinical features and pT3 disease: univariate and
5; PIRADS 2–3 versus PIRADS 4–5.
pT3
Yes N (%) No N (%) P
Age
∗
63.0 (±8.7) 62.4 (±6.6)
Clinical stage
cT1a-1c 39 (63%) 163 (85%)
cT2a-2c 23 (37%) 29 (15%)
PSA
∗
6.4 (±2.2) 5.9 (±1.8)
PIRADS
2 1 (2%) 10 (5%)
3 6 (10%) 39 (21%)
4 17 (27%) 85 (44%)
5 38 (61%) 58 (30%)
Margins at FSA
Negative 32 (52%) 148 (77%)
Positive 30 (48%) 44 (23%)
Age
∗
63.0 (±8.7) 62.4 (±6.6)
Clinical stage
cT1a-1c 39 (63%) 163 (85%)
cT2a-2c 23 (37%) 29 (15%)
PSA
∗
6.4 (±2.2) 5.9 (±1.8)
PIRADS
2–3 7 (11%) 49 (26%)
4–5 55 (89%) 143 (74%)
Margins at FSA
Negative 32 (52%) 148 (77%)
Positive 30 (48%) 44 (23%)
Signiﬁcant ORs and P values are in bold.
∗
= (± SD).
† T test for continuous variables; x2 test or Fisher exact test for categorical variables.
‡Mantel–Haenszel P value for trend: <0.0001.
xMantel–Haenszel P value for trend: 0.02.
6not intended to receive a nerve-sparing, had it after mpMRI
suggested its feasibility: no PSM occurred in these patients.[29]
Also, Hricak et al[30] evidenced that MRI may support the
surgeon in deciding to perform a nerve-sparing procedure.
Our results are consistent with the available results. PIRADS 5
lesions are associated with EPE and PSM at FSA or ﬁnalmultivariate analyses; PIRADS 2–3 versus PIRADS 4 versus PIRADS
value† Multivariate odds ratio (95% CI) P value
0.28 0.98 (0.94–1.03) 0.41
0.001 0.002
1.00 (reference)
3.20 (1.56–6.59)
0.18 1.15 (0.97–1.36) 0.11
0.0003‡
1.00 (reference)
1.17 (0.44–3.12) 0.21
3.41 (1.33–8.72) 0.001
0.0001 0.004
1.00 (reference)
2.59 (1.35–4.94)
0.28 0.99 (0.95–1.03) 0.64
0.001 0.001
1.00 (reference)
3.28 (1.62–6.60)
0.18 1.16 (0.99–1.37) 0.07
0.02x 0.11
1.00 (reference)
2.05 (0.84–4.98)
0.0001 0.001
1.00 (reference)
2.80 (1.49–5.25)
[31,32] [33]
Figure 3. Comparison between ROC curves for pT3 for (A) all PIRADS score (P=0.12); (B) PIRADS 2–3 versus PIRADS 5 (P=0.18). PIRADS = Prostate Imaging
Reporting and Data System, ROC = receiver operating characteristics.
Bianchi et al. Medicine (2016) 95:40 www.md-journal.compathology. Interestingly, these conclusions are drawn from
patients who would have been otherwise classiﬁed as low-risk
and so eligible for nerve-sparing surgery.
In this perspective, mpMRI could be used in combination with
a variety of biomarkers, ranging from the well-known prostate
cancer antigen 3 (PCA3) and 2proPSA-prostate health in-Table 8
Association between the features of the patients with GS ≥7 at ﬁnal
Gleason Score ≥7
Yes N (%) No N (%) P
Age∗ 63.2 (±7.3) 61.9 (±7.0)
Clinical stage
cT1a-1c 97 (75%) 105 (84%)
cT2a-2c 32 (25%) 20 (16%)
PSA∗ 6.3 (±1.9) 5.9 (±1.9)
PIRADS
2 3 (2%) 8 (6%)
3 14 (11%) 31 (25%)
4 49 (38%) 53 (43%)
5 63 (49%) 33 (26%)
FSA <
Negative 77 (60%) 103 (82%)
Positive 52 (40%) 22 (18%)
Age∗ 63.2 (±7.3) 61.9 (±7.0)
Clinical stage
cT1a-1c 97 (75%) 105 (84%)
cT2a-2c 32 (25%) 20 (16%)
PSA∗ 6.3 (±1.9) 5.9 (±1.9)
PIRADS
2–3 17 (13%) 39 (31%)
4–5 112 (87%) 86 (69%)
FSA <
Negative 77 (60%) 103 (82%)
Positive 52 (40%) 22 (18%)
Univariate and multivariate analyses with PIRADS 2–3 versus 4 versus 5; PIRADS 2–3 versus 4–5. Sig
∗= (± SD).
† T test for continuous variables; x2 test or Fisher exact test for categorical variables.
‡Mantel–Haenszel P value for trend: <0.0001.
xMantel–Haenszel P value for trend: 0.0005.
7dex to the experimental urotensin II receptor, which
have been suggested to be useful tools for the reclassiﬁcation of
otherwise “low-risk” prostate cancers.
The present study has some limitations. First, we did not
report functional outcomes and long-term oncologic follow-up.
Second, our dataset did not include body mass index andpathology and PIRADS score. .
value† Multivariate odds ratio (95% CI) P value
0.06 1.01 (0.98–1.05) 0.51
0.10 0.34
1.00 (reference)
1.39 (0.70–2.73)
0.11 1.09 (0.95–1.25) 0.23
0.0003‡
1.00 (reference)
1.96 (0.96–3.97) 0.86
3.47 (1.66–7.24) 0.002
0.0001 0.001
1.00 (reference)
2.70 (1.48–4.93)
0.06 1.02 (0.98–1.05) 0.39
0.10 0.29
1.00 (reference)
1.43 (0.73–2.80)
0.11 1.10 (0.96–1.26) 0.18
0.0005x 0.006
1.00 (reference)
2.53 (1.31–4.88)
0.0001 0.0007
1.00 (reference)
2.81 (1.55–5.10)
niﬁcant ORs and P values are in bold.
Figure 4. Comparison between ROC curves for GS ≥7 at ﬁnal pathology with (A) all PIRADS scores (P=0.04); (B) PIRADS 2–3 versus PIRADS 4–5
(P=0.03).
Bianchi et al. Medicine (2016) 95:40 Medicineprostatic volume, which can inﬂuence the incidence of
PSM.[34,35] Third, we did not consider the presence of multiple
lesions at mpMRI, assuming that the “index lesion” was
representative of the disease as a whole. Fourth, we did
not discuss the problem of costs, which are an issue whenTable 9
Association between features of the patients and upstaging and/or
versus 4 versus 5; PIRADS 2–3 versus 4–5.
Upstaging and/or upgrading
Yes N (%) No N (%) P
Age∗ 62.9 (±7.5) 62.1 (±6.8) 0
Clinical stage 0
cT1a-1c 110 (75%) 92 (85%)
cT2a-2c 36 (25%) 16 (15%)
PSA∗ 6.2 (±2.0) 5.9 (±1.8) 0
PIRADS <0
2 3 (2%) 8 (7%)
3 17 (12%) 28 (26%)
4 53 (36%) 49 (46%)
5 73 (50%) 23 (21%)
FSA <0
Negative 89 (61%) 91 (84%)
Positive 57 (39%) 17 (16%)
Age∗ 62.9 (±7.5) 62.1 (±6.8) 0
Clinical stage 0
cT1a-1c 110 (75%) 92 (85%)
cT2a-2c 36 (25%) 16 (15%)
PSA∗ 6.2 (±2.0) 5.9 (±1.8) 0
PIRADS 0
2–3 20 (14%) 36 (33%)
4–5 126 (86%) 72 (67%)
FSA
Negative 89 (61%) 91 (84%)
Positive 57 (39%) 17 (16%) <0
Signiﬁcant ORs and P values are in bold.
∗= (± SD).
† T test for continuous variables; x2 test or Fisher exact test for categorical variables.
‡ Deﬁned as GS ≥7 (upgrading) and or pathological staging >pT2 (upstaging).
xMantel–Haenszel P value for trend<0.0001.
jjMantel–Haenszel P value for trend 0.0002.
8planning to perform an mpMRI for every patient with prostate
cancer.
Despite these limitations, our study provided interesting results
that can support the construction of new models to predict the
appropriateness of a nerve-sparing procedure.upgrading‡: univariate and multivariate analysis with PIRADS 2–3
value† Multivariate odds ratio (95% CI) P value
.23 1.00 (0.96–1.04) 0.89
.12 0.24
1.00 (reference)
1.54 (0.75–3.14)
.26 1.05 (0.91–1.21) 0.49
.0001x
1.00 (reference)
1.78 (0.89–3.55) 0.47
4.72 (2.24–9.96) <0.0001
.0001 0.001
1.00 (reference)
2.90 (1.53–5.52)
.23 1 (0.97–1.04) 0.86
.12 0.19
1.00 (reference)
1.59 (0.79–3.19)
.26 1.07 (0.93–1.23) 0.36
.0002jj 0.002
1.00 (reference)
2.70 (1.42–5.12)
0.0005
1.00 (reference)
.0001 3.05 (1.62–5.73)
standardised scoring system of multiparametric magnetic resonance
Figure 5. Comparison between ROC curves for upgrading (GS≥7) and/or upstaging (> pT2) with (A) all PIRADS scores (P=0.01); (B) PIRADS 2–3 versus 4–5 (P=
0.02).
Bianchi et al. Medicine (2016) 95:40 www.md-journal.com5. Conclusions
The present study showed how mpMRI and FSA could predict
upgrading, upstaging, and extraprostatic extension.
MpMRI could be part of new predictive models whose aim is
to correctly classify patients preoperatively, while FSA could
improve surgical strategy to obtain the best oncologic and
functional outcomes.
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